A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Part 1 (HV Population): Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive. Exclusion Criteria: * Clinically relevant evidence or history of illness or disease. * Pregnant or nursing females. * History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection. * A positive urine drug screen at screening or Day -1. * Current tobacco smokers or use of tobacco within 3 months prior to screening. * Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy). * History of regular alcohol consumption. * Receipt of any vaccine, an investigational agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose. This includes agents administered during clinical trial participation. Part 2 (HBV Population): Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 70 years, inclusive * HBV DNA levels: * A Screening HBV DNA level in serum/plasma that is \<LLOQ and * No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an approved test) * CHB subjects must have been on their prescribed HBV NUC treatment with no change in regimen for 12 months prior to Screening Exclusion Criteria: * A documented prior diagnosis of cirrhosis * Pregnant or nursing females * Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV * Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases